{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(3)"],"submitter":["Lagneaux E"],"pubmed_abstract":["<h4>Background</h4>Venous malformations (VMs) are commonly associated with localized intravascular coagulopathy leading to elevated D-dimer and risks of hemorrhagic and thromboembolic events, particularly in extensive lesions. While low-molecular-weight heparin (LMWH) has been effective in managing coagulopathy and pain, direct oral anticoagulants (DOACs) emerge as a promising alternative.<h4>Objectives</h4>This study aims to evaluate the efficacy and safety of DOACs in treating VMs associated with localized intravascular coagulopathy, offering a comparative perspective to LMWH.<h4>Methods</h4>A retrospective study was conducted on 29 patients with VMs and secondary localized intravascular coagulopathy treated with DOACs between 2013 and 2023 in a single tertiary center specialized in vasc"],"journal":["Research and practice in thrombosis and haemostasis"],"pagination":["102400"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11087699"],"repository":["biostudies-literature"],"pubmed_title":["Direct oral anticoagulants and venous malformations: literature review and retrospective study of 29 patients."],"pmcid":["PMC11087699"],"pubmed_authors":["Boon LM","Hermans C","Lagneaux E","Vikkula M","Revencu N"],"additional_accession":[]},"is_claimable":false,"name":"Direct oral anticoagulants and venous malformations: literature review and retrospective study of 29 patients.","description":"<h4>Background</h4>Venous malformations (VMs) are commonly associated with localized intravascular coagulopathy leading to elevated D-dimer and risks of hemorrhagic and thromboembolic events, particularly in extensive lesions. While low-molecular-weight heparin (LMWH) has been effective in managing coagulopathy and pain, direct oral anticoagulants (DOACs) emerge as a promising alternative.<h4>Objectives</h4>This study aims to evaluate the efficacy and safety of DOACs in treating VMs associated with localized intravascular coagulopathy, offering a comparative perspective to LMWH.<h4>Methods</h4>A retrospective study was conducted on 29 patients with VMs and secondary localized intravascular coagulopathy treated with DOACs between 2013 and 2023 in a single tertiary center specialized in vasc","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-06-02T11:33:12.336Z","creation":"2026-05-27T03:12:00.963Z"},"accession":"S-EPMC11087699","cross_references":{"pubmed":["38738172"],"doi":["10.1016/j.rpth.2024.102400"]}}